Group 1 - The company held its 9th meeting of the 2nd Supervisory Board on June 26, 2025, with all three supervisors present, and the meeting was conducted in accordance with relevant laws and regulations [1][2] - The Supervisory Board approved a proposal to increase the investment amount for certain fundraising projects and to permanently supplement working capital with surplus raised funds, which aligns with the company's future operational development plans [1][2] - The voting results for the proposal were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2] Group 2 - The decision to adjust the investment total for the "Fluid Equipment Component Manufacturing Project" and conclude it was deemed beneficial for improving the efficiency of fund utilization and in the interest of the company and all shareholders [1] - The meeting's resolutions were documented and are available for review, ensuring transparency and compliance with regulatory requirements [2]

证券代码：301261 证券简称：恒工精密 公告编号：2025-021 河北恒工精密装备股份有限公司 第二届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 河北恒工精密装备股份有限公司（以下简称"公司"）第二届监事会第九次 会议于 2025 年 6 月 26 日下午 14:00 在公司二楼第四会议室以现场方式召开， 本次监事会会议通知已于 2025 年 6 月 23 日以邮件或通讯形式发出。会议应到 监事 3 人，实到监事 3 人，董事会秘书列席了会议。会议由监事会主席付永晟 先生主持。本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定，表决所形成的决议合法、有效。 二、监事会会议审议情况 全体监事经过充分审议，以书面记名投票表决方式通过了以下议案。 （一）审议通过了《关于增加部分募投项目投资额并结项暨节余募集资金 永久补充流动资金的议案》 经审议，监事会认为：公司调整"流体装备零部件制造项目"投资总额并结 项及将节余募集资金永久补充流动资金，符合公司未来经营发展规 ...

证券代码：301261 证券简称：恒工精密 公告编号：2025-023 河北恒工精密装备股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一）审议通过了《关于增加部分募投项目投资额并结项暨节余募集资金 永久补充流动资金的议案》 经审议，董事会认为本次公司调整"流体装备零部件制造项目"投资总额并 结项及节余募集资金永久补充流动资金是根据当前的市场环境、公司业务发展规 划及项目实施的实际需要而做出的审慎决策，有助于提高募集资金使用效率，不 存在损害公司及股东利益的情形，不会对公司的正常生产经营产生重大不利影响。 董事会同意对"流体装备零部件制造项目"投资额增加至 42,936.29 万元，将该 项目结项并将节余募集资金 34.16 万元永久补充流动资金，详见公司同日刊登于 巨潮资讯网（www.cninfo.com.cn）上的《关于增加部分募投项目投资额并结项 暨节余募集资金永久补充流动资金的公告》（公告编号：2025-022）。 保荐机构中信证券股份有限公司对此事项出具了核查意见。 表决结果：同意 7 票，反对 0 票 ...

中信证券股份有限公司 关于河北恒工精密装备股份有限公司 1 业经立信会计师事务所（特殊普通合伙）验证，并于 2023 年 7 月 3 日出具了《河 北恒工精密装备股份有限公司验资报告》（信会师报字[2023]第 ZB11232 号）。 公司依照相关规定对募集资金进行了专户存储管理，并与保荐机构以及募集资金 专户监管银行签署了募集资金专户存储三方/四方监管协议。 根据公司《首次公开发行股票并在创业板上市招股说明书》中披露的募集资 金用途和公司董事会、监事会或股东大会审议通过的《关于调整募集资金投资项 目拟投入募集资金金额的议案》《关于增加部分募投项目投资额及调整募投项目 内部投资结构的议案》，公司首次公开发行股票募集资金具体投资项目如下： 二、本次拟增加投资额及调整内部投资结构的募投项目的具体情况 （一）本次拟增加投资额的募集资金已使用情况 截至 2025 年 6 月 25 日，本次拟调整的募投项目募集资金使用情况如下： 增加部分募投项目投资额并结项暨节余募集资金永久补充 流动资金的核查意见 河北恒工精密装备股份有限公司（以下简称"公司"或"恒工精密"）于 2025 年 6 月 26 日分别召开第二届董事会第九 ...

证券代码：301261 证券简称：恒工精密 公告编号：2025-022 河北恒工精密装备股份有限公司 关于增加部分募投项目投资额并结项暨节余募集资金永久补充 流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 河北恒工精密装备股份有限公司（以下简称"公司"或"恒工精密"）于 2024 年 9 月 12 日召开了 2024 年第一次临时股东大会，审议通过了《关于增加 部分募投项目投资额及调整募投项目内部投资结构的议案》，同意使用自有资金 9,290.97 万元增加募集资金投资项目中的"流体装备零部件制造项目"和"流 体装备核心部件扩产项目"投资额并调整其募投项目内部投资结构的事项。 公司 现根据募集资金投资项目实际投入情况，公司于 2025 年 6 月 26 日分别召 开第二届董事会第九次会议、第二届监事会第九次会议审议通过了《关于增加部 分募投项目投资额并结项暨节余募集资金永久补充流动资金的议案》，同意将"流 体装备零部件制造项目"投资额增加至 42,936.29 万元，将该项目结项并将节余 募集资金 34.16 万元永久补充流动资金。公司监事会对 ...

Core Viewpoint - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 2.50 per 10 shares, totaling RMB 21,972,549.00, approved by the shareholders' meeting on May 23, 2025 [1][2]. Group 1: Profit Distribution Plan - The profit distribution plan approved by the shareholders' meeting involves a cash dividend of RMB 2.50 per 10 shares, amounting to a total distribution of RMB 21,972,549.00 [1][2]. - The distribution will not include stock dividends or capital reserve transfers to increase share capital [1]. - The total number of shares eligible for profit distribution remains unchanged from the time of the announcement until the implementation date [2]. Group 2: Implementation Details - The implementation of the profit distribution plan is consistent with the approved plan and its adjustment principles [2]. - The record date for the distribution is set for June 26, 2025, and the ex-dividend date is June 27, 2025 [2][3]. - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies [3]. Group 3: Taxation and Adjustments - The cash dividend will be subject to different tax rates based on the type of shareholder, with specific provisions for overseas investors and different holding periods [2]. - Following the distribution, the minimum selling price for shares held by certain shareholders will be adjusted to RMB 35.90 per share [3].

证券代码：301261 证券简称：恒工精密 公告编号：2025-020 河北恒工精密装备股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 河北恒工精密装备股份有限公司（以下简称"公司"、"恒工精密"）2024 年度权益分派方案已获 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 （一）公司 2024 年度股东大会审议通过的利润分配方案为：以公司总股本 87,890,196 股为基数，向全体股东每 10 股派发现金红利人民币 2.50 元（含税）， 合计派发现金红利人民币 21,972,549.00 元（含税），本次利润分配不送红股， 不以公积金转增股本。如在分配预案披露之日起至实施权益分派股权登记日期间， 公司享有利润分配权的股本总额发生变化（如公司总股本由于可转债、股份回购、 股权激励行权、再融资新增股份上市等原因发生变化的），公司拟按每股分配比 例不变的原则，相应调整分红总额。本次利润分配后，公司剩余可供分配利润结 转以后 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

金十数据6月12日讯，恒工精密公告称，公司董事、财务总监、董事会秘书刘东计划减持不超过79375 股，占公司股份总数的0.09%；副总经理袁建华计划减持不超过50000股，占公司股份总数的0.06%；监 事会主席付永晟计划减持不超过6250股，占公司股份总数的0.01%。 恒工精密：部分董事、监事及高级管理人员计划减持股份 ...

恒工精密（301261）公告，股东刘东、袁建华及付永晟计划自公告披露之日起15个交易日后的3个月 内，通过集中竞价方式分别减持不超过79375股、50000股、6250股，分别占公司总股本的0.09%、 0.06%、0.01%。此次减持因个人资金需求，不会导致公司控制权变更，也不会对公司治理结构、股权 结构及持续性经营产生重大影响。减持计划符合相关法律法规规定，减持实施具有不确定性。 ...